Skip to main content
Sonoma Pharmaceuticals, Inc. logo

Sonoma Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · SNOA ISIN · US83558L2043 US Manufacturing
Open in API
Filings indexed 951 across all filing types
Latest filing 2019-12-31 Board/Management Inform…
Country US United States of America
Listing US SNOA

About Sonoma Pharmaceuticals, Inc.

https://sonomapharma.com/

Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and commercializes products based on its patented Microcyn® Technology, a stabilized hypochlorous acid (HOCl) platform. With over 20 years of experience, the company produces a range of prescription and over-the-counter solutions for advanced wound care, dermatology, animal health, and eye care. Its products are designed to manage various conditions by promoting healing and reducing the risk of infection. The portfolio serves healthcare professionals in settings like hospitals and nursing homes, as well as consumers for at-home use.

Recent filings

Filing Released Lang Actions
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes details about bonus stock option grants to executives, a new employment agreement with the CEO, and an amendment to the company's Code of Ethics. These topics relate to changes in senior management and executive compensation arrangements. There is no detailed financial data or comprehensive financial statements present, so it is not an Annual Report (10-K) or Interim Report (IR). The document is not a proxy statement or voting results announcement. The primary focus is on management changes and related agreements, which fits the Board/Management Information category (MANG). The document length is sufficient and contains substantive information about management changes rather than just an announcement or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). Therefore, the best classification is MANG with high confidence.
2019-12-31 English
FORM S-8
Capital/Financing Update Classification · 100% confidence The document is a Form S-8 registration statement filed with the SEC by Sonoma Pharmaceuticals, Inc. It registers securities to be offered under employee stock incentive plans. The document includes details about the stock plans, registration fee calculation, incorporation by reference of other SEC filings, indemnification provisions, and exhibits. Form S-8 is a registration statement used for securities issued under employee benefit plans and is not a financial report, earnings release, or management discussion. It is a capital/financing related filing concerning the registration of securities for employee plans. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is not a mere announcement or certification but a substantive registration statement.
2019-12-26 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 26, 2019, by Sonoma Pharmaceuticals, Inc. It reports the entry into a material definitive agreement related to a public offering of common stock, including details about the placement agency agreement, shares sold, pricing, fees, and warrants issued. The document does not contain financial statements or detailed financial performance data but rather announces a financing transaction and related agreements. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes. The document length is about 10,499 characters, which is substantive and not a mere announcement of a report. Therefore, the appropriate classification is CAP with high confidence.
2019-11-29 English
PROSPECTUS SUPPLEMENT
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(3) related to a public offering of common stock by Sonoma Pharmaceuticals, Inc. It includes detailed information about the offering, risk factors, use of proceeds, and other related disclosures typical of a securities offering document. The presence of terms like "prospectus supplement," "public offering price," "shares of common stock," and references to the Securities and Exchange Commission (SEC) filings indicate this is a capital raising document. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document is not an annual report, earnings release, or any other type of report but specifically a financing prospectus supplement.
2019-11-27 English
PROSPECTUS SUPPLEMENT
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(3) related to a public offering of common stock by Sonoma Pharmaceuticals, Inc. It includes detailed information about the offering, risk factors, use of proceeds, and other related disclosures typical of a capital raising document. The presence of terms like "prospectus supplement," "offering price," "shares of common stock," and references to placement agents and use of proceeds clearly indicate this is a capital/financing update document. It is not an annual report, earnings release, or any other type of report but specifically a filing related to a securities offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence level.
2019-11-26 English
FORM 10-Q
Interim / Quarterly Report Q2 2019
2019-11-14 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.